|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:major_depressive_disorder
2008
|
|
gptkbp:ATCCode
|
N06AX23
|
|
gptkbp:CASNumber
|
93413-62-8
|
|
gptkbp:chemicalFormula
|
C16H25NO2
|
|
gptkbp:contraindication
|
use with MAO inhibitors
allergy to desvenlafaxine
|
|
gptkbp:developedBy
|
gptkb:Wyeth_Pharmaceuticals
|
|
gptkbp:drugClass
|
norepinephrine reuptake inhibitor
|
|
gptkbp:eliminationHalfLife
|
11 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:form
|
100 mg
25 mg
50 mg
|
|
gptkbp:genericName
|
gptkb:desvenlafaxine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pristiq
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin and norepinephrine
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionForm
|
extended-release tablet
|
|
gptkbp:relatedTo
|
gptkb:venlafaxine
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
hypertension
suicidal thoughts (in young adults)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
constipation
dizziness
insomnia
dry mouth
hyperhidrosis
|
|
gptkbp:bfsParent
|
gptkb:Desvenlafaxine
|
|
gptkbp:bfsLayer
|
7
|